PATENT	APPLICATION	SERIAL	NO.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

01/22/2002 JBALINAN 00000201 10046396

01 FC:101 02 FC:103

740.00 OP 990.00 OP

ľŲ

CONTINUING APPLICATION TRANSMITTAL UNDER RULE 1.53(b) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

108184-00017

January 16, 2002

Customer No 3004372

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

1050 Connecticut Avenue, N.W.,

Suite 400

Washington, DC 20036-5339 Telephone: (202) 857-6000 Facsimile: (202) 638-4810

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is a

□ Continuation

☐ Divisional

☐ Continuation-in-Part

Docket No.

Date:

application of prior pending Application No. 09/736,027, filed December 21, 2000,

For (Title):

THIOPHENE AND FURAN 2.5-DICARBOXAMIDES USEFUL IN THE

TREATMENT OF CANCER

By (Inventors):

Denis LABRECQUE, Sterge LAMOTHE, Marc COURCHESNE, Kaval CHAN,

Giorgio ATTARDO and Karen MEEROVITCH

- A Declaration and Power of Attorney is attached. The attached Declaration and Power of 1. \boxtimes Attorney is:
 - a. A copy of the Declaration and Power of Attorney from the parent application. (Used with 冈 the same or fewer inventors and (a) a copy of the prior application or (b) a revised, reformatted or edited version of the prior application that does not contain new matter.)
 - b. A new Declaration and Power of Attorney. (Used with the same, fewer or additional inventors and (a) a copy of the prior application, (b) a revised, reformatted or edited version of the prior application that does not contain new matter, or (c) a new specification.)
- 2. The filing fee based on entry of the concurrently filed Preliminary Amendment is calculated \boxtimes below:

CLAIMS IN THE APPLICATION AFTER ENTRY OF ANY PRELIMINARY AMENDMENT NOTED BELOW

			
NO. FILED	NO. EXTRA		
75 - 20	= 55		
1 -3	= 0		
☐ MULTIPLE DEPENDENT CLAIMS PRESENTED			
	75 - 20 1 - 3		

^{*} If the difference is less than zero, enter "0".

SMALL ENTITY				
RATE	FEE	<u>OR</u>		
	\$ 370	<u>OR</u>		
x 9 =	\$	<u>OR</u>		
x 42=	\$	<u>OR</u>		
+140 =	\$	<u>OR</u>		
TOTAL	\$	<u>OR</u>		

OTHER THAN A SMALL ENTITY

RATE	FEE
	\$ 740
x 18	\$990
x 84	\$
+280	\$
TOTAL	\$ 1730

- 3. A Check in the amount of \$1730.00 to cover the filing fee is attached. The Commissioner 冈 is hereby authorized to charge any other fees that may be required to complete this filing, or to credit any overpayment, to Deposit Account No. 01-2300.
- 4. __ of the application before calculating the filing fee. At least one independent claim is retained for filing purposes.



Rule 1.53(b) Continuing Application of U.S. Application No. 09/736,027 Filed December 21, 2000

	5.	\bowtie	Amend the specification by inserting before the first line the sentence:
as			This is a \(\subseteq \text{Continuation } \subseteq \text{Division } \subseteq Continuation-in-Part of Application No. 09/736,027 filed December 21, 2000, which in turn is a 371 of International Application PCT/WO00/00486 filed January 6, 2000. The disclosure of the prior application(s) is hereby incorporated by reference herein in its entirety
	6.		Formal drawings (Figs) are attached.
	7.		Priority of foreign application No. filed in is claimed under 35 U.S.C. §119 and/or §365(b).
	8.		The certified copy was filed in prior Application No. 09/403,021 from the International Bureau.
	9.		A certified copy of the above foreign application(s) is attached.
	10.		Priority of U.S. Provisional Application(s) No filed is claimed under 35 U.S.C. §119(e).
	11.		Amend the specification by inserting before the first line the sentence:
			This nonprovisional application claims the benefit of U.S. Provisional Application(s) No filed
-i-	12.	\boxtimes	The prior application is assigned of record to <u>BioChem Pharma Inc.</u> recorded at Reel <u>011530</u> , Frame <u>0049</u> on <u>December 21, 2000</u> .
	13.		This application is filed by fewer than all the inventors named in the prior application (37 C.F.R §1.53(b)(1)). Delete the following inventor(s) named in the prior application:
Ų	14.		A Preliminary Amendment is attached.
10 (n	15.		An Information Disclosure Statement is attached along with Form PTO-1449 and references.
: (3	16.		Small entity status:
': d • ±			a. A small entity statement is attached.
¦≐ (N			 b. A small entity statement was filed in the parent application and such status is still proper and desired.
5			C. Small entity status is no longer claimed.
ľ U	17.		Other:
	18.		The Power of Attorney in the application is to Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; Richard J. Berman, Reg. No. 39,107; Murat Ozgu, Reg. No. 44,275; Robert K. Carpenter, Reg. No. 34,794; Gregory B. Kang, Reg. No. 45,273; Rustan Hill, Reg. No. 37,351; Hans J. Crosby, Reg. No. 44,634; Brian A. Tollefson, Reg. No. 46,338; David D. Dzara, Reg. No. 47,543, Lynne D. Anderson, Reg. No. 46,412, Michael A. Steinberg, Reg. No. 43,160 and Lynn A. Bristol, Reg. No. 48,898.

Rule 1.53(b) Continuing Application of U.S. Application No. 09/736,027 Filed December 21, 2000

19. Address all future communications to:

CUSTOMER NO. 004372 ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 CONNECTICUT AVENUE, N.W., SUITE 400 WASHINGTON, D.C. 20036-5339

Respectfully submitted,

D. Daniel Dzara, II

Registration No. 47,543

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

Enclosure: Petition for Extension of Time (3 months)